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Immune systemAutoimmune diseases are a range of diseases in which the immune response to self-antigens results in
damage or dysfunction of tissues. Autoimmune diseases can be systemic or can affect speciﬁc organs
or body systems. For most autoimmune diseases there is a clear sex difference in prevalence, whereby
females are generally more frequently affected than males. In this review, we consider gender differences
in systemic and organ-speciﬁc autoimmune diseases, and we summarize human data that outlines the
prevalence of common autoimmune diseases speciﬁc to adult males and females in countries commonly
surveyed. We discuss possible mechanisms for sex speciﬁc differences including gender differences in
immune response and organ vulnerability, reproductive capacity including pregnancy, sex hormones,
genetic predisposition, parental inheritance, and epigenetics. Evidence demonstrates that gender has a
signiﬁcant inﬂuence on the development of autoimmune disease. Thus, considerations of gender should
be at the forefront of all studies that attempt to deﬁne mechanisms that underpin autoimmune disease.
 2014 Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Autoimmune disease, ﬁrst recognized by Ian Mackay and
Macfarlane Burnet, is characterized by the failure of an organism
to tolerate its own cells and tissues, resulting in an aberrant
immune response by lymphocytes and/or antibodies (Mackay
and Burnet, 1963). This leads to pathological changes and dysfunc-
tion of the tissue that is the target of the self-directed immune
response. Autoimmune diseases can be systemic or can affect
speciﬁc organs or body systems including the endocrine, gastro-
intestinal and liver, rheumatological, and neurological systems. In
this review, we discuss systemic and organ-speciﬁc autoimmune
diseases. In general there is a greater prevalence of autoimmune
disease in females than males, although there are exceptions. To
demonstrate sex differences in autoimmune disease, we summa-
rize human data to provide an overview of the prevalence in males
and females of common autoimmune diseases in countries
commonly surveyed. We then discuss possible mechanisms for
sex speciﬁc differences.1.1. Autoimmunity and autoimmune disease – key considerations for
sexual dimorphism
Autoimmune diseases comprise a range of diseases in which the
immune response to self-antigens results in damage or dysfunction
of tissues (Mackay and Burnet, 1963). Criteria have been developed
that allow a disease to be classiﬁed as autoimmune (Rose and
Bona, 1993). These criteria include the identiﬁcation of a target
antigen, the presence of antibodies and/or T cells in the target
organ, and the transfer of disease to animals by cells or antibodies
(Rose and Bona, 1993; Witebsky et al., 1957). The immune system
is comprised of multiple cell types of a single lineage. Collectively,
these cells contribute to acquired and innate immunity. Interac-
tions between acquired and innate immune function may aggra-
vate autoimmune responses. A strong inﬂammatory component,
with inﬁltration of tissue with macrophages and lymphocytes, is
associated with many organ-speciﬁc autoimmune diseases, such
as in rheumatoid arthritis (RA) and multiple sclerosis (MS). Non-
inﬂammatory conditions like myasthenia gravis (MG) are anti-
body-mediated, although there may be some minor lymphocyte
inﬁltration. Systemic lupus erythematosus (SLE) is another impor-
tant antibody-mediated disease.
The origin of autoimmune disease is a disruption of immune
tolerance of self-antigens. This is thought to occur in genetically
susceptible individuals after exposure to environmental triggers
(Mackay, 2001). Autoimmune diseases are strongly associated with
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could involve genetic variability in the immune response and
genetic variability in the ability to present antigens (Gough and
Simmonds, 2007). Modern genetic studies of autoimmune diseases
such as MS, type I diabetes (T1D) and inﬂammatory bowel disease
(IBD) have shown that many other genes, each with small effect,
also contribute to genetic susceptibility to autoimmunity
(Australia and New Zealand Multiple Sclerosis Genetics, 2009;
Barrett et al., 2009; Khor et al., 2011). At times autoimmune dis-
eases run in families (Bias et al., 1986; McCombe et al., 1990). This
was once thought to indicate an autosomal dominant inheritance,
but it is now thought to be due to the interaction of common genes
(Clayton, 2009). However, what is often overlooked is that a very
signiﬁcant component of the genetic contribution to autoimmunity
is gender, with the presence or absence of a Y chromosome inﬂu-
encing the risk for autoimmune disease.
Environmental factors also predispose to autoimmune disease.
This is well illustrated by twin studies, where the risk of develop-
ing autoimmune disease cannot be solely explained by genetics.
For example, in MS there is greater concordance in monozygotic
than dizygotic twins, indicating that genetic factors are important
(Willer et al., 2003). However, the concordance in monozygotic
twins is incomplete, suggesting a role for environmental factors.
In a study from Finland, it was shown that the concordance of
MS in dizygotic twins has increased in two decades, with this rapid
increase again suggesting a signiﬁcant role for environmental fac-
tors (Kuusisto et al., 2008). Possible environmental factors that
predispose to autoimmunity include exposure to infectious agents
and to dietary components (Lamb et al., 2008; Pender and Greer,
2007), exposure to chemicals, xenobiotics or toxins (Rieger and
Gershwin, 2007), stress (Rieger and Gershwin, 2007), or reduced
exposure to factors that protect from the development of autoim-
mune diseases (e.g. sunlight during childhood and adulthood)
(Fraser et al., 2003; Ponsonby et al., 2005). Different exposure or
response to these environmental factors could contribute to gender
differences in autoimmunity.2. Sexual dimorphism in autoimmune diseases – prevalence
and consequence
2.1. Effect of gender on the prevalence of autoimmune diseases
For most autoimmune diseases there are clear sex differences in
prevalence whereby females are generally more frequently
affected than males (Eaton et al., 2007). This gender bias can be
modest, as is seen in MS (Bentzen et al., 2010; Cheng et al.,
2009; El Adssi et al., 2012; Hadjimichael et al., 2008; McCombe,
2003; Osoegawa et al., 2009; Pandit and Kundapur, 2014;
Ramagopalan et al., 2013), or strong, as is seen in primary biliary
cirrhosis (PBC) (Amarapurkar and Patel, 2007; Eaton et al., 2007;
Harada et al., 2013; McNally et al., 2011; Shen et al., 2009; Sood
et al., 2004). Importantly, prevalence between males and females
may be changing. For example, the predominance of MS in females
is increasing; initial early reports suggest equal prevalence in
males and females (Buckley, 1954), by the 1980’s prevalence was
approximately 2:1 (female:male) (Confavreux et al., 1980), and
recent reports suggest prevalence in some instances of up to 3:1
(female:male) (Ramagopalan et al., 2013). Such a rapid change is
likely to be due to environmental factors. To provide a more
detailed assessment of the current status of gender bias in autoim-
mune diseases, we summarize adult data from recent studies,
focusing predominantly (when possible) on the United States
(USA), England, France, Denmark, Japan, China, India, and Australia.
Measures are further categorized based on systemic, endocrine,
gastrointestinal, neurological or rheumatological diseases (Fig. 1).Data highlight the very high (9:1) gender bias toward females
for systemic autoimmune diseases including SLE (Chiche et al.,
2012; Eaton et al., 2007; Feldman et al., 2013; Li et al., 2012;
Ramagopalan et al., 2013) and Sjögren’s syndrome (SS) (Eaton
et al., 2007; Misra et al., 2003; Nannini et al., 2013; Ramagopalan
et al., 2013; Seror et al., 2013; Tsuboi et al., 2013; Xiang and Dai,
2009), occurring independent of country of assessment. By con-
trast, some neurological diseases (including MG (Guptill et al.,
2011; Guy-Coichard et al., 2008; Huang et al., 2013; Pedersen
et al., 2013; Ramagopalan et al., 2013; Singhal et al., 2008;
Suzuki et al., 2011) and Guillain–Barré syndrome (GBS)
(Alshekhlee et al., 2008; Chen et al., 2014; Dhadke et al., 2013;
Eaton et al., 2007; Mitsui et al., 2013)) had a near equal prevalence
in males and females, although recent data suggest a greater prev-
alence of GBS in males in Asian countries including Japan (Mitsui
et al., 2013), China (Chen et al., 2014) and India (Dhadke et al.,
2013). In our recent study of GBS in Australia, there was a male
preponderance (Blum et al., 2013). However, in MS, the most com-
mon neurological autoimmune disease, females accounted for two
thirds of all cases (Bentzen et al., 2010; Cheng et al., 2009; El Adssi
et al., 2012; Hadjimichael et al., 2008; McCombe, 2003; Osoegawa
et al., 2009; Pandit and Kundapur, 2014; Ramagopalan et al., 2013).
Again, this occurred mostly independent of country of assessment.
The prevalence of endocrine related autoimmune diseases pre-
dominantly favored females (including Grave’s Disease (GD)
(Carle et al., 2011; Gaujoux et al., 2006; Guo et al., 2013;
Phitayakorn et al., 2013) and Hashimoto’s thyroiditis (HT)
(Ramagopalan et al., 2013; Zhang et al., 2012)). This was not the
case for T1D (Anderson et al., 2012; Bhadada et al., 2011; Eaton
et al., 2007; Kawasaki and Eguchi, 2004; Menke et al., 2013), where
prevalence was equal in males and females. This varied somewhat
between countries, and prevalence slightly favored males in the
USA (Menke et al., 2013) and Denmark (Eaton et al., 2007), but
females in Japan (Kawasaki and Eguchi, 2004) and Australia
(Speight et al., 2012). Prevalence for rheumatological autoimmune
diseases varied greatly between countries, however trends
remained the same. For ankylosing spondylitis (AS), prevalence
favored males in the USA (Reveille, 2011), England (Ramagopalan
et al., 2013), China (Xiang and Dai, 2009), India (Aggarwal and
Malaviya, 2009), and Australia (Oldroyd et al., 2009). For RA prev-
alence greatly favored females, with reports ranging from 66% to
86% dominance (Biver et al., 2009; Li et al., 2012; Myasoedova
et al., 2011; Pedersen et al., 2011; Ramagopalan et al., 2013;
Yamanaka et al., 2013). Of the gastrointestinal diseases that we
studied, PBC showed a strong female dominance (values ranging
from 80% to 100%), regardless of country (Amarapurkar and Patel,
2007; Eaton et al., 2007; Harada et al., 2013; McNally et al.,
2011; Shen et al., 2009; Sood et al., 2004). While celiac disease
was generally female dominant (60% to 80% incidence), an excep-
tion was the recent observations by Nijhawan et al. (2013) that
found a 60% incidence for adult males (Nijhawan et al., 2013). A
similar rate of prevalence in male children was reported
(Bhattacharya et al., 2013). Incidence of ulcerative colitis (UC)
and Crohn’s disease (CD) in males and females did not vary greatly
by country, and generally did not favor females or males
(Gathungu et al., 2012; Jain et al., 2012; Jess et al., 2007; Nerich
et al., 2006; Ng et al., 2013; Ramagopalan et al., 2013; Zhao
et al., 2013). Of interest, Asakura et al. (2009) showed a deviation
in this trend, with 70% CD subjects in Japan being male (Asakura
et al., 2009). The studies detailed above do not consider severity
of symptoms.
2.2. Effect of gender on the severity of autoimmune diseases
As well as prevalence varying with gender, the severity of
autoimmune diseases, meaning the severity of symptoms and the
Fig. 1. Prevalence of autoimmune disease in USA, England, France, Denmark, Japan, China, India, and Australia. There is a very high gender bias toward females for systemic
diseases including systemic lupus erythematosus (Chiche et al., 2012; Eaton et al., 2007; Feldman et al., 2013; Li et al., 2012; Ramagopalan et al., 2013) and Sjögren’s
syndrome (Eaton et al., 2007; Misra et al., 2003; Nannini et al., 2013; Ramagopalan et al., 2013; Seror et al., 2013; Tsuboi et al., 2013; Xiang and Dai, 2009). Neurological
diseases including myasthenia gravis (Guptill et al., 2011; Guy-Coichard et al., 2008; Huang et al., 2013; Pedersen et al., 2013; Ramagopalan et al., 2013; Singhal et al., 2008;
Suzuki et al., 2011) and Guillain–Barré syndrome (Alshekhlee et al., 2008; Chen et al., 2014; Dhadke et al., 2013; Eaton et al., 2007; Mitsui et al., 2013) have near parity
distribution between males and females, although recent data suggests a greater prevalence of Guillain–Barré syndrome in males in Japan (Mitsui et al., 2013), China (Chen
et al., 2014) and India (Dhadke et al., 2013). In Australia, there is a male preponderance in Guillain–Barré syndrome (Blum et al., 2013). For multiple sclerosis, females account
for two thirds of all cases (Bentzen et al., 2010; Cheng et al., 2009; El Adssi et al., 2012; Hadjimichael et al., 2008; McCombe, 2003; Osoegawa et al., 2009; Pandit and
Kundapur, 2014; Ramagopalan et al., 2013). The prevalence of endocrine related diseases predominantly favors females (including Grave’s Disease (Carle et al., 2011; Gaujoux
et al., 2006; Guo et al., 2013; Phitayakorn et al., 2013) and Hashimoto’s thyroiditis (Ramagopalan et al., 2013; Zhang et al., 2012)). Prevalence is near parity for type 1 diabetes
(Anderson et al., 2012; Bhadada et al., 2011; Eaton et al., 2007; Kawasaki and Eguchi, 2004; Menke et al., 2013), although prevalence slightly favors males in the USA (Menke
et al., 2013) and Denmark (Eaton et al., 2007), or females in Japan (Kawasaki and Eguchi, 2004) and Australia (Speight et al., 2012). Prevalence for rheumatological diseases
varies between countries, however trends remained the same. For ankylosing spondylitis, prevalence favors males in the USA (Reveille, 2011), England (Ramagopalan et al.,
2013), China (Xiang and Dai, 2009), India (Aggarwal and Malaviya, 2009), and Australia (Oldroyd et al., 2009). For rheumatoid arthritis, prevalence greatly favors females
(Biver et al., 2009; Li et al., 2012; Myasoedova et al., 2011; Pedersen et al., 2011; Ramagopalan et al., 2013; Yamanaka et al., 2013). Primary biliary cirrhosis shows a strong
female dominance (Amarapurkar and Patel, 2007; Eaton et al., 2007; Harada et al., 2013; McNally et al., 2011; Shen et al., 2009; Sood et al., 2004). Celiac disease is generally
female dominant, although prevalence seems to favor males in India (Nijhawan et al., 2013). Incidence of ulcerative colitis (UC) and Crohn’s disease (CD) in males and females
does not vary greatly by country, and generally does not favor females or males (Gathungu et al., 2012; Jain et al., 2012; Jess et al., 2007; Nerich et al., 2006; Ng et al., 2013;
Ramagopalan et al., 2013; Zhao et al., 2013), although a deviation in this trend is seen in Japan (Asakura et al., 2009).
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However, compared to prevalence, this is not easily deﬁned. The
effect of gender on severity varies among autoimmune diseases.
For example, psoriasis is more severe in males (Sakai et al.,
2005). Men develop autoimmune hepatitis at a younger age and
have high relapse rates, but also have better prognosis than women
(Al-Chalabi et al., 2008). By contrast, the clinical course in CD ismore severe in girls (Gupta et al., 2007), whereas in diseases like
RA, gender does not necessarily predict outcome (Courvoisier
et al., 2008). In MS, disease severity, measured as disability pro-
gression, appears to be greater in males (Runmarker and
Andersen, 1993; Weinshenker et al., 1991). A recent study demon-
strates greater disease severity in male SLE patients; male patients
were more likely to suffer renal and cardiovascular co-morbidities
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infections, hypothyroidism, depression, esophageal reﬂux, asthma,
and ﬁbromyalgia (Crosslin and Wiginton, 2011).Fig. 2. Factors underlying sexual dimorphism in autoimmune disease. While the
underlying basis for sexual dimorphism in autoimmune disease is yet to be
determined, a number of factors may contribute to gender differences in autoim-
mune disease. Females show increased immune reactivity, differences in the
number or responsiveness of cells that constitute the immune response, and
differential resistance to target organ damage, and this may inﬂuence propensity to
autoimmune disease. Hormonal changes during pubertal maturation, pregnancy,2.3. Effect of gender on the pathological features of autoimmune
disease
Gender differences are reported in the T cell and antibody
responses that occur in autoimmune disease. In MS for instance,
females tend to secrete higher levels of IFNc in response to prote-
olipid protein (PLP) peptides when compared to control females
and males with MS (Pelfrey et al., 2002), and increased T-cell reac-
tivity occurs at a higher frequency (Greer et al., 2004). On the other
hand, a small study in SLE patients report that the IgM and IgG
reactivity to dsDNA Ro and La follows no gender bias (Ferreira
et al., 2005). In diabetes, females have higher levels of antibodies
to glutamic acid decarboxylase (Lindholm et al., 2004).
There are no systematic studies of the effects of gender on the
histopathological features of autoimmune disease, but it has been
suggested that autoimmune disease in males is young onset, with
acute inﬂammation and autoantibodies, while in females autoim-
mune disease is either acute onset and non-inﬂammatory and/or
associated with chronic pathology (Fairweather et al., 2008). Much
remains to be studied in this area.and menopause may alter susceptibility to autoimmunity, and it is generally
accepted that pregnancy is associated with improved symptoms in autoimmune
disease. The protective effects that are exerted by female (estrogen, progesterone,
and prolactin) and male (androgens) hormones may also explain gender differences
in speciﬁc autoimmune diseases. Differential exposure to environmental factors
(including sunlight) can inﬂuence the prevalence and risk of developing an
autoimmune disease or the severity of disease. Genetic factors that might inﬂuence
the gender speciﬁc development of autoimmune disease may be related to
susceptibility genes, chromosomal differences, or epigenetics. When genetic factors
are combined with environmental factors, this can inﬂuence parental inheritance of
autoimmune disease. Epigenetic changes that arise in autoimmune disease can be
related to the sex of the parent, or can result from external factors. Genetic
imprinting, and in particular, miRNA imprinting, could also contribute to the sexual
dimorphism seen in autoimmune disease.2.4. Effect of gender on survival in autoimmune disease
Autoimmune diseases are generally not considered to be fatal,
but in many diseases, reduced life expectancy can be demon-
strated, compared to the general population. The measure of this
is the standarized mortality rate (SMR), which compares the
observed mortality in a group with that expected in that popula-
tion. This has been well studied in MS where survival duration is
greater for women than men. However, when survival is consid-
ered and adjusted relative to general mortality rates, females with
MS have poorer survival outcomes (Grytten Torkildsen et al.,
2008). In T1D, relative mortality was found to be higher for Finnish
women than for men (Asao et al., 2003). Increased mortality in a
large multicentre international cohort of SLE patients have been
reported to be associated with female gender (Bernatsky et al.,
2006). Similar observations were documented in a Spanish popula-
tion (Ruiz et al., 2014). For PBC, a higher number of deaths have
been observed in English/Welsh women (Hamlyn and Sherlock,
1974). While data suggests that gender can inﬂuence the mortality
of autoimmune disease, it is important to note that co-morbidities
may signiﬁcantly alter the course of disease. Moreover, survival
can be inﬂuenced by factors other than severity of disease, such
as quality of care, age of onset, and time to diagnosis.3. Factors underlying sexual dimorphism in autoimmune
diseases
Above we have described the observable effects of gender on
the incidence and severity of autoimmune disease. Now we will
consider the possible underlying mechanisms that could lead to
these clinical effects. We limit our considerations to human obser-
vations and refer to mouse data when human data is restricted. We
have previously provided an extensive review of data pertaining to
mouse models of autoimmune disease (McCombe et al., 2009). The
underlying basis for sexual dimorphism in autoimmune disease is
yet to be determined. However, signiﬁcant research has investi-
gated the impact of differences between males and females in
the immune response, organ vulnerability, reproductive function,
microchimerism, sex hormones, and the environment on theprevalence, susceptibility and severity of autoimmune disease
(Fig. 2). These factors are discussed below.
3.1. Differences between female and male immune systems
The gender differences in autoimmunity could be due to differ-
ences between male and female immune systems (McCombe and
Greer, 2013a). Such differences are found in most animal species;
males have immune suppression when compared to females and
this is linked to male sexual activity (McKean and Nunney,
2005). Females show increased immune reactivity (Hewagama
et al., 2009), and this greater immunocompetence may translate
to greater resilience to infectious and some non-infectious dis-
eases. However, it is possible that this greater immune reactivity
makes women more prone to developing autoimmune disease
(Zandman-Goddard et al., 2007).
3.1.1. T lymphocytes, B lymphocytes and natural killer cells
T lymphocytes, B lymphocytes and natural killer (NK) cells com-
prise the lymphocytes of the immune system. T lymphocyte
secreted cytokines including IL-2, IL-4, IL-10, IFNc and TNFa
underlie cell-mediated adaptive immunity. B lymphocytes produce
IgG and IgM antibodies against foreign antigens to mount antibody
driven adaptive immune responses. NK cells are effectors of cell-
mediated, innate immunity.
While there are age-associated changes in human lymphocyte
subtype numbers (Yan et al., 2010), the overall number of lympho-
cytes in males and females is the same. However, males have a
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menopausal women have decreased numbers of B lymphocytes
and helper T cells (Th cells) (Giglio et al., 1994; Yang et al.,
2000). B lymphocyte counts do not differ between genders, how-
ever, women produce higher levels of circulating antibodies than
men (Rowley and Mackay, 1969), which could underlie their pro-
pensity to produce higher levels of autoantibodies in autoimmune
diseases (Whitacre et al., 1999). Indeed, females have increased
levels of IgM when compared to their male counterparts
(Butterworth et al., 1967; Lichtman et al., 1967). While data on
NK cells is limited, when compared to men, fertile females have
decreased NK cell cytotoxic activity, but women with premature
menopause have higher numbers of NK cells (Giglio et al., 1994).
Females produce stronger humoral and cellular immune
responses to antigen than males (Ansar Ahmed et al., 1985). Stud-
ies in humans suggest that females produce higher levels of
CD4 + T cells in response to immunization (Ho et al., 1995). More-
over, the antibody response of females surpasses that of males
after vaccination for inﬂuenza, hepatitis B, rubella and tetanus
(Cook, 2008). In some instances, adverse effects in response to
immunization can be observed in females in the absence of a sig-
niﬁcant humoral response (Shohat et al., 2000).
Gender differences are also seen in the outcome of immunity to
bacterial, parasitic, and viral infections. With bacterial infections,
decreased production of anti-lipoarabinomannan IgM is observed
in males with Mycobacterium tuberculosis infections (Demkow
et al., 2007). In secondary syphilis, females are more resistant as
CD4 + and CD8 + T lymphocytes are both elevated (Ho et al.,
1995). The prevalence, severity or susceptibility of parasitic infec-
tions, Schistosoma mansoni, Schistosoma haematobiainfections (Degu
et al., 2002), and Leishmania donovani (Goble and Konopka, 1973) is
greater in males than females. The decreased prevalence and
severity of Schistosoma infections in females may be attributed to
their ability to secrete greater amounts of anti-inﬂammatory cyto-
kines and differing antibody isotypes (Demkow et al., 2007), and
the decreased susceptibility in females to Leishmania may be due
to increased secretion of granulocyte macrophage colony-stimulat-
ing factor (Lezama-Davila et al., 2007). In the case of viruses, stud-
ies illustrate higher prevalence of herpes simplex virus type 2 in
females (Glynn et al., 2008; Howard et al., 2003; Rabenau et al.,
2002), and this may be due to higher levels of progesterone in
females since progesterone contraceptives hastens herpes simplex
virus type 1 (Stringer et al., 2007) (the role of progesterone in auto-
immunity will be discussed below). Increased levels of lympho-
cytes and neutrophils in young females (Pembrey et al., 2008)
may underlie their increased susceptibility to hepatitis C virus
(European Paediatric Hepatitis, 2005; Zanetti et al., 1998), although
chronic adult hepatitis C virus infection results in increased ﬁbrosis
in males (Poynard et al., 1997).
3.1.2. Microglia, astrocytes, mast cells, and dendritic cells
The immune cells of that are resident in tissues could poten-
tially show gender differences that could inﬂuence autoimmune
disease. Little is known about gender differences in these cells.
To illustrate this issue we will use examples from the CNS. Microg-
lia and astrocytes account for the majority of the brain cell popula-
tion, and there is no indication of any gender difference with
respect to the spatial distribution of these cell types in the male
and female brain (Stark et al., 2007). While microglia represent
the primary immune cell of the central nervous system, astrocytes
are also considered to be immunocompetent, as they possess the
ability to synthesize immune molecules in response to insult/
injury (Farina et al., 2007; Gimsa et al., 2013; Jensen et al., 2013;
Kaur et al., 2010; Pivneva, 2008; Wirenfeldt et al., 2011). In the
context of immunity, mast cells and dendritic cells are also of par-
ticular importance. Mast cells are resident in a multitude of tissuesincluding the brain (Silverman et al., 2000; St John and Abraham,
2013) and take part in the host innate immune defence by releas-
ing chemoattractants that recruit eosinophils (Wardlaw et al.,
1986) and monocytes (Perry et al., 1993). Dendritic cells, which
are the antigen-presenting cells of the immune system, are gener-
ally present on tissues that are exposed to the environment
(Banchereau and Steinman, 1998; Silverman et al., 2000), but they
have also recently been suggested to be resident in brain (albeit
mouse brain) (Bulloch et al., 2008).
A number of in vivo studies provide insight into the roles of
microglia, astrocytes, mast cells, and dendritic cells in the neuro-
immune response in general. Interestingly, such studies have also
generated observations that might be of relevance when consider-
ing gender differences in autoimmune disease. For example: estro-
gen inhibits microglia and astrocyte activation in the striatum of a
mouse model of Parkinson’s Disease (Tripanichkul et al., 2006);
astrocytes in female mice may be more resistant to oxidative
stress-induced toxicity (Giordano et al., 2013), estrogen increases
the number and activation of mast cells in the brain (Boes and
Levy, 2012), and female mice have increased recruitment of den-
dritic cells to the brain after stroke (Manwani et al., 2013).
In the context of autoimmunity, studies in mice suggest that
estrogen may play a key role in the activation of microglia and
astrocytes, and the generation of tolerogenic dendritic cells. Myelin
basic protein-primed T cells from female mice and castrated male
mice induce microglial expression of proinﬂammatory cytokines
(Dasgupta et al., 2005), expression of the RNA binding protein
HuR in spinal cord astrocytes provides greater attenuation of dis-
ease in female experimental autoimmune encephalomyelitis
(EAE) mice (and this is reversed following ovariectomy) (Wheeler
et al., 2012), an estrogen receptor alpha ligand reduces inﬂamma-
tion and protects against axonal loss and reactive astrogliosis in
EAE mice (Spence et al., 2011), and estriol leads to the generation
of splenic dendritic cells that when transferred to mice prior to
active induction of EAE leads to protection from the development
of EAE (Papenfuss et al., 2011).
Data pertaining to human autoimmune disease is currently
limited to astrocytes and dendritic cells. Astrocytes in the rim
and center of MS lesions in male and female patients have recently
been found to upregulate different gender steroid-speciﬁc
enzymes, suggesting that these responses might underlie gender-
speciﬁc differences in steroid synthesis and signaling in the brains
of MS patients, and thus, the gender bias in MS prevalence and sus-
ceptibility (Luchetti et al., 2014). While dendritic cell numbers are
reported to be lower in MS (de Andres et al., 2009), primary SS
(Vogelsang et al., 2010), and SLE (Henriques et al., 2012), whether
there are gender differences in the expression or function of den-
dritic cells in these diseases remains unknown. Thus, future
research that aims to determine whether gender differences in
autoimmune disease can be attributed to differential expression
and function of microglia, astrocytes, mast cells, and dendritic cells
will generate signiﬁcant interest.
3.2. Sexual dimorphism in target organ vulnerability to damage
Autoimmune disease results when an autoimmune attack on
target organs leads to dysfunction. Autoimmunity can occur with-
out clinical disease being evident. This means that there are two
issues involved in the development of autoimmune disease: the
presence of autoimmunity and the ability of the target organ to
resist the autoimmune attack. For example, in SLE, the presence
of autoantibodies does not always lead to end organ damage
(Lewis et al., 2013). The role of the target organ in autoimmunity
has been reviewed elsewhere (Hill et al., 2007). To consider gender
differences in the target organ that could lead to gender differences
in the incidence and severity of autoimmune disease, we need to
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to tolerate damage. The processes that lead to an ability to with-
stand damage is sometimes referred to as cytoprotection; or neu-
roprotection or cardioprotection when referring to the ability of
the nervous system or the heart, respectively, to withstand dam-
age. A full discussion of this topic is beyond the scope of this
review, but the processes involved are fundamental and include
susceptibility to apoptosis, autophagy (Lista et al., 2011), mito-
chondrial function (Martel et al., 2012), and biochemical pathways
that promote survival such as the nrf2 pathway (Chen and Kunsch,
2004; Lee et al., 2005).
There are some studies that indicate that there are gender dif-
ferences in the ability to protect cells from damage. In general it
is thought that females have greater resistance, because of the
cytoprotective properties of estrogen (see below). Much of the
work in this area has been done in the nervous system, although
estrogen also has protective properties on endothelium (Si et al.,
2001). It is generally accepted that females tend to have improved
outcome after traumatic brain injury (Groswasser et al., 1998), and
although this has been debated (Bayir et al., 2004; Farace and
Alves, 2000; Wagner et al., 2000), this is thought to occur in
response to the effects of estrogen (Roof and Hall, 2000). While less
is known about gender differences in the processes and pathways
involved in neuroprotection, there is a study suggesting that there
are gender differences in autophagy (Lista et al., 2011). Additional
research is needed to determine in more detail whether gender
differences that target organ resistance are responsible for gender
differences in autoimmune disease.3.3. Autoimmune disease and reproductive function
Reproductive load may signiﬁcantly alter susceptibility to auto-
immunity, particularly in females. Careful consideration relative to
pubertal maturation (thus the onset of mature reproductive age),
and life events that alter reproductive function (including
pregnancy and menopause) should be made. For pregnancy, these
considerations extend to that of the fetus. We now survey the data
relating to reproductive issues and autoimmune disease.3.3.1. Puberty
The incidence of autoimmune disease varies relative to the
onset of reproductive function, although with the exception of epi-
demiological studies, few studies differentiate between pre-puber-
tal and post-pubertal incidence, speciﬁcally in relation to gender
bias. This is surprising, given the impact of puberty on gender bias
in autoimmune diseases. For example, while pre-pubertal onset of
MS is rare, with only 3–5% of cases reported in individuals under
18 years of age (Chitnis et al., 2009; Duquette et al., 1987; Ghezzi
et al., 1997), gender bias within these cases of MS is absent
(reviewed in (Chitnis, 2013)). Following the onset of puberty, how-
ever, incidence changes rapidly and pubertal girls are found to be
at greater risk of developing MS than pre-pubertal girls
(Ramagopalan et al., 2010). Moreover, earlier onset of puberty in
girls is also associated with increased risk of developing MS
(Ramagopalan et al., 2009b). However, in SLE, the male to female
ratio of 1:9 may be as low as 1:2 prior to puberty (reviewed in
(Tedeschi et al., 2013)). By contrast, the incidence of UC in adoles-
cents is equivalent in males and females, but by early-adulthood
the ratio of male to female patients is 4:1 (Bove, 2013). These
reports could suggest that exposure to hormonal changes during
pubertal development could underlie the gender bias in autoim-
mune diseases. However, environmental effects may also play a
role. For example, relocation from a low-risk geographic to high-
risk geographic area during puberty signiﬁcantly increased MS risk
(Dean and Elian, 1997). Although this was not gender speciﬁc, it isan example of how factors other than hormones could inﬂuence
the effect of puberty on disease.3.3.2. Pregnancy
Pregnancy involves physiological changes in the mother,
including elevation of cardiac output, increased basal metabolic
rate, increased lipid levels, and weight gain (Forsum and Lof,
2007; Granger, 2002; Lain and Catalano, 2007; Tan and Tan,
2013). In pregnancy there are changes in the levels of hormones
such as estriol, progesterone, prolactin, early pregnancy factor
(EPF), alpha-fetoprotein (Brunton and Russell, 2010) and leptin
(Molvarec et al., 2011), and elevated levels of growth factors such
as insulin-like growth factor (IGF) (Lauszus et al., 2003). After
delivery, there is a rapid decline in the levels of pregnancy hor-
mones and maternal physiology rapidly returns to normal,
although during lactation the levels of prolactin and oxytocin are
elevated (Uvnas-Moberg et al., 1990). It is generally thought that
the changes in maternal physiology are mediated through the
effects of the pregnancy hormones. In pregnancy, the mother plays
host to the fetus, which contains foreign antigens. Immune
changes in pregnancy tend to suppress the maternal immune
system, which is thought to be important in preventing rejection
of the fetus (Munoz-Suano et al., 2011; Veenstra van
Nieuwenhoven et al., 2003; Yip et al., 2006).3.3.2.1. Immune responses in pregnancy. Regulatory T cells (Tregs)
mediate active immune tolerance to prevent any maternal lym-
phocyte-mediated damage to the fetus (Aluvihare et al., 2004;
Saito et al., 2005). A shift in Th1/Th2 activity in pregnancy favors
increased Th2-related and reduced Th1-related activities. This
results in an improvement in Th1-mediated diseases and an exac-
erbation of Th2-mediated diseases (Doria et al., 2002, 2004;
Ostensen et al., 2005). Indeed, the remission of the Th1 diseases
RA and AS during pregnancy is coupled with an inhibition of
Th1-related activities via an upregulation in cytokine inhibitors
(Ostensen et al., 2005). These ﬁndings are further corroborated
by a Th1 phenotype in abortion, and a Th2 phenotype during nor-
mal pregnancy (Raghupathy, 2001). While it is accepted that the
Th1/Th2 paradigm is a marker for pregnancy success, it has been
superseded by the Treg/Th17 paradigm. In 2004, Tregs were found
to be elevated during normal pregnancy (Somerset et al., 2004).
Elevated levels of Tregs correlate well with decreased activity of
Th1-related autoimmune diseases (Forger et al., 2008). The ratio
of Treg and IL-17 appears to be of pivotal importance during preg-
nancy as an imbalance in the Treg/IL-17 proportion is linked to
complications during pregnancy, including recurrent pregnancy
loss and pre-eclampsia (Darmochwal-Kolarz et al., 2012; Saito
et al., 2011). It is likely that steroid hormones drive these immuno-
logical changes in pregnancy; improvements in psoriasis (Th1-
dependent disease) is correlated with higher levels of estrogen
(Murase et al., 2005), and the increase in Tregs may be driven by
estradiol since low levels of Tregs are positively correlated with
low levels of estradiol in patients with missed abortion (Cao
et al., 2014). The steroid-associated immunological changes seen
in pregnancy may very well contribute to sex differences in auto-
immune disease, as discussed below.
Another pregnancy-associated change that may underlie gender
differences in autoimmune disease is a small protein of the heat
shock family, chaperonin 10 (cpn 10) (heat shock protein 10, hsp
10). Cpn 10 is released into blood during early pregnancy
(Morton et al., 1977). In line with its immunomodulatory capacity,
a 12 week course of cpn 10 treatment improves disease measures
in patients with RA (Vanags et al., 2006). Moreover, decreased T
lymphocyte-associated secretion of TNFa and interleukin 1b
occurs after 12 weeks of cpn 10 in psoriasis (Vanags et al., 2006).
Fig. 3. Microchimerism and autoimmunity. Microchimerism is the trafﬁcking of
cells from the fetus to the mother and vice versa. Fetal microchimerism has been
proposed to have a beneﬁcial role in helping a parous woman to recover from injury
through the provision of additional mutipotential stem cells that could be used in
repair of damage. By contrast, maternal microchimerism may be harmful since
maternal cells are a possible source of graft versus host response, as is seen in
systemic sclerosis. Since microchimerism occurs during pregnancy, microchimer-
ism may contribute to gender differences in autoimmune disease.
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effects of pregnancy on autoimmune disease.
3.3.2.2. Autoimmune disease and pregnancy. The effects of preg-
nancy on autoimmune disease differ for inﬂammatory autoimmune
diseases, which tend to remit, and antibody mediated autoimmune
diseases, where the effects are more variable. For instance, the
symptoms of MG vary considerably from woman to woman and
from pregnancy to pregnancy in the same woman (Hantai et al.,
2004), and pregnancy has been reported to worsen, improve, or
provide no change in MG symptoms (Batocchi et al., 1999). Like-
wise, pregnancy with psoriasis can lead to similar variations in dis-
ease response (Murase et al., 2005). In AS, pregnancy may not
aggravate disease (Lui et al., 2011), but it has been reported to cause
remission (Ostensen and Ostensen, 1998). For CD, the activity of
disease was signiﬁcantly lower during pregnancy as determined
by the Harvey-Bradshaw index (Agret et al., 2005). In MS
(Borchers et al., 2010; Confavreux et al., 1998; McCombe and
Greer, 2013b), and RA (Hench, 1983; Nelson and Ostensen, 1997;
Ostensen and Villiger, 2007) however, it is widely accepted that
pregnancy is associated with the remission of symptoms, although
there can be a ﬂare of disease post-partum. In contrast to MS and
RA, SLE an antibody mediated disease, is reported to worsen during
pregnancy (Ruiz-Irastorza et al., 1996; Stojan and Baer, 2012), and
this can vary in the degree of severity (Lateef and Petri, 2012).
Pregnancy can also trigger the onset of autoimmune disease.
Fulminant autoimmune diabetes can present during pregnancy
or in the post-partum period (Inagaki et al., 2002), and other dor-
mant autoimmune diseases, like thyroiditis, can become clinically
evident post-partum (Muller et al., 2001; Premawardhana et al.,
2004; Thompson and Farid, 1985). With evidence indicating a role
of pregnancy in autoimmune disease, it must be noted however
that heterogeneous study designs, variable presentation of disease,
and patient ethnicity can render the interpretation of pregnancy-
associated data difﬁcult.
Autoimmune disease during pregnancy can also result in fetal
manifestations of disease. This is seen in diseases including MG
(Eymard et al., 1991; Gveric-Ahmetasevic et al., 2008), SLE (Lee,
2009; Yildirim et al., 2013), thyrotoxicosis (Batra, 2013; Radetti
et al., 2002), autoimmune thrombocytopenic purpura (Sukenik-
Halevy et al., 2008; van der Lugt et al., 2013) and cutaneous lupus
(Johnson, 2013). When placental transmission of autoantibodies
occurs, a temporary autoimmune disease can occur in the neonate.
In more severe cases, passively acquired autoimmunity can result
in congenital heart block due to transplacental transfer of anti-Ro
and anti-La from mothers with SLE (Brucato et al., 2001;
Wahren-Herlenius and Sonesson, 2006), or, from transfer of acetyl-
choline receptors antibodies, in arthrogryposis multiplex congenita
(Donaldson et al., 1981) or pulmonary hypoplasia (Newsom-Davis,
2007). Thus, given fetal complications associated with pregnant
mothers with autoimmune disease, due care is required for the
management of disease during the gestational period.
Autoimmune disease can also appear under conditions of
assisted pregnancy and ovarian hyperstimulation. Increased MS
activity and relapses of MS can occur after assisted reproductive
technology (ART) (Correale et al., 2012; Hellwig et al., 2008;
Laplaud et al., 2006), and this may be due to stress, immunological
changes in response to hormone therapy, or termination of
immune therapy upon the instigation of ART. ART pregnancies
have also been associated with exacerbation of SLE (Ben-Chetrit
and Ben-Chetrit, 1994; Casoli et al., 1997). Furthermore, complica-
tions can arise in autoimmune patients undergoing ART. Women
with thyroid antibodies before the ﬁrst cycle of ART have increased
risk of miscarriage (Poppe et al., 2003), and a trend toward worse
pregnancy and live-birth rate is becoming evident in SLE mothers
undergoing ART (Costa and Colia, 2008).As detailed above, current data indicates that the differential
effects imparted by pregnancy in autoimmune diseases are very
speciﬁc to autoimmune disease type. While it has been suggested
that some autoimmune diseases are not improved by pregnancy
(Adams Waldorf and Nelson, 2008), this is generally only the case
for SLE, which is an antibody mediated disease. We note that preg-
nancy is documented to exert protective effects in AS, CD, MS, and
RA, which are inﬂammatory diseases. In particular, there is over-
whelming evidence to demonstrate that pregnancy is associated
with improved symptoms in MS and RA.3.3.2.3. Pregnancy, microchimerism and autoimmunity. Microchim-
erism, the trafﬁcking of cells from the fetus to the mother and vice
versa, occurs during pregnancy (Lo et al., 1996). It is well known
that, as a normal phenomenon, fetal cells persist in the maternal
circulation years after pregnancy (fetal microchimerism) (Bianchi
et al., 1996), and that maternal cells persist in immunodeﬁcient
and immunocompetent offspring into adult life (maternal
microchimerism) (Evans et al., 1999; Maloney et al., 1999). Micro-
chimerism has been considered to be a possible trigger for autoim-
munity and has also been put forward as a protective mechanism
(Fig. 3).
If microchimerism were indeed linked to the development of
autoimmune disease, then chimeric cells may persist as inactive
dendritic cells and lymphocytes (McNallan et al., 2007) until an
environmental factor, a shift in cytokine proportion, an infection,
or a hormonal trigger activates these cells, thereby causing an allo-
graft reaction, and subsequently, autoimmune disease in either the
mother or the offspring (Nelson, 1999, 2002). The evidence for a
role for fetal microchimerism in the development of autoimmune
disease is conﬂicting. Fetal microchimeric cells have been found
in the blood and thyroid of women with autoimmune thyroid dis-
ease (Lepez et al., 2012; Renne et al., 2004). Lepez and colleagues
have also demonstrated that these fetal cells in women with thy-
roid disease were cytotoxic T lymphocytes, and hence, may have
been capable of initiating a graft-vs-host reaction to elicit autoim-
mune thyroid disease (Lepez et al., 2011). In line with a role for
fetal micochimerism, women with increased odds of developing
autoimmune thyroid disease were noted to have had a previous
pregnancy (Friedrich et al., 2008), but Bulow-Pederson and col-
leagues found no association between pregnancy and autoimmune
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between fetal microchimerism and autoimmune disease (Bulow
Pedersen et al., 2006).
The disease that has been most studied with respect to a caus-
ative role for fetal microchimerism is systemic sclerosis (sclero-
derma) given that chronic graft-vs-host disease after bone
marrow transplantation results in clinical presentations that are
similar to systemic sclerosis (Artlett et al., 1998; Gratwohl et al.,
1977). Much like the studies for thyroid disease however, those
that have investigated microchimerism as an underlying cause
for systemic sclerosis have presented variable results (Ichikawa
et al., 2001; Murata et al., 1999). Maternal microchimerism may
present as tissue-speciﬁc maternal microchimerism in neonates,
as has been suggested to be the case in neonatal lupus congenital
heart block (Stevens et al., 2003). The rate of maternal microchim-
erism is also higher in twins with MS (Willer et al., 2006). By con-
trast, maternal microchimerism appears to play no role in PBC
(Nomura et al., 2004).
Fetal microchimerism has also been proposed to have a
beneﬁcial role in helping a parous woman to recover from injury.
Microchimeric cells have been demonstrated at sites of tissue
inﬂammation during pregnancy, forming blood vessels. After deliv-
ery, microchimeric cells have been found in the maternal liver after
liver injury, and many years after pregnancy, microchimeric fetal
cells have been found at sites of injury where these cells adopt a
variety of phenotypes (indicating their multipotent capacity). This
transfer of fetal stem cells could be helpful and provide additional
mutipotential stem cells that could be used in repair of damage
(Guillot et al., 2007; Johnson and Bianchi, 2004; Khosrotehrani
and Bianchi, 2005; Khosrotehrani et al., 2004; Lo et al., 1996). This
is speculative, but further investigation could be rewarding.
3.3.2.4. Long-term effects of pregnancy on autoimmunity. Another
consideration in autoimmune disease is the long-term effect of
pregnancy. There is little information in this area, except in the
case of MS. Overall, women with MS who have been pregnant have
a better long-term outcome than those who have not been preg-
nant (D’Hooghe et al., 2010). It seems that the effects are cumula-
tive since multiparous women seem to have a better outcome than
women with fewer, or who have no pregnancies (Runmarker and
Andersen, 1995; Verdru et al., 1994). Having been pregnant does
not increase the risk of secondary progression of disease (Koch
et al., 2009). Women who have children with different partners
do not have greater risk of disability as might be expected to occur
if the immune response to paternal genes was harmful (Basso et al.,
2004). Of interest, recent ﬁndings suggested that pregnancy fre-
quency lowers mortality in T1D (Sjöberg et al., 2013). This awaits
further validation, as it is a difﬁcult topic to evaluate. There may
be reverse causation at work, such that women with less severe
disease could be more likely to decide to have children. However
there are some plausible biological mechanisms for long-term ben-
eﬁcial effects of pregnancy, including fetal microchimerism which
could provide a reservoir of stem cells that could aid in repair (as
discussed above), and epigenetic changes (as discussed below).
3.3.3. Menopause
Menopause is a natural occurrence that marks the end of cycli-
cal changes associated with reproductive function in women. It is
characterized by lower levels of estrogens and progesterone, peak-
ing of FSH levels, follicular depletion, and irreversible cessation of
menses. There are conﬂicting reports about the effects of meno-
pause on MS that has developed earlier in life (Holmqvist et al.,
2006) (Smith and Studd, 1992; Wundes et al., 2011). In SLE,
however, menopausal transition has been reported to decrease
the frequency of ﬂares, but to cause more damage in the organs
in which individual postmenopausal ﬂares occur (Fernandezet al., 2005; Sanchez-Guerrero et al., 2001; Urowitz et al., 2006).
In RA, postmenopausal women report higher physical disability
scores than premenopausal women (Kuiper et al., 2001). Meno-
pause has also been associated with the onset of autoimmune dis-
ease. For example, autoimmune hepatitis occurs most frequently in
the late teenage years in males, but occurs in women in the late
teens and after menopause (Werner et al., 2008). By contrast, men-
opause is not associated with high occurrence of SLE (Mok, 2008),
and SLE after menopause is generally less severe (Boddaert et al.,
2004). Early menopause however has shown to be associated with
an increased risk of developing SLE and RA (Costenbader et al.,
2007; Pikwer et al., 2012a,b). There are a number of immunological
changes associated with menopause including increased produc-
tion and response to pro-inﬂammatory cytokines, decreased secre-
tion of anti-inﬂammatory cytokines, decreased lymphocyte levels,
and decreased activity of NK cells (Gameiro and Romao, 2010;
Gameiro et al., 2010). These changes, coupled with altered endo-
crine function, may underlie the incidence and risk of autoimmune
disease that is associated with menopausal transition.
3.4. Role of hormones in the sexual dimorphism in autoimmunity
The strong gender bias in autoimmune disease susceptibility
could be due to the differential effects of gender-speciﬁc
hormones. Indeed, a considerable amount of evidence now demon-
strates not only the role of gender-speciﬁc hormones in contribut-
ing to disease, but also the differential roles of these hormones
relative to altered reproductive states (Fig. 4). For example, disease
ﬂares for SLE are inﬂuenced by the age of onset of menarche, the
use of oral contraceptives, the age of onset of menopause, and
hormonal treatments in response to menopause (Costenbader
et al., 2007). These changes in reproductive function are all charac-
terized by signiﬁcant changes in the hormonal milieu. The effects
of various sex hormones including estrogens, progesterone, andro-
gens, and prolactin are considered below. When possible, we will
discuss evidence of contribution to immunity, contribution to
autoimmune disease, and outcomes following treatments targeting
these hormones.
3.4.1. Estrogens
Acting through estrogen receptor subtypes (ERs) alpha (ERa)
and beta (ERb), estrogen mediates transcription activity of intracel-
lular machinery to produce genomic effects, whereas the rapid,
non-genomic actions of estrogen are triggered through activation
of membrane-associated ERs (mER). This results in changes in
intracellular activity that occur independent of transcription
pathways and protein synthesis. Endogenous estrogens include
estrogen (E1), estradiol (E2) and estriol (E3, produced only in preg-
nancy). These compounds differentially act on intracellular ERs
that are present in all cells of the immune system (Deroo and
Korach, 2006), including T and B lymphocyte subsets, and periph-
eral NK cells (Pernis, 2007; Pierdominici et al., 2010).
It has become clear that estrogens impact immunity by modu-
lating lymphocyte development and function (Grimaldi et al.,
2002; Smithson et al., 1998). Indeed, estrogens may facilitate
critical protective effects that negate detrimental changes follow-
ing inﬂammatory responses. For example, a decrease in CD4+/
CD8 + T-cell-subset ratios in cultures of human lymphocytes is
seen following estrogen treatment (Athreya et al., 1993). Similarly,
estrogen enhances immunoglobulin secretion from these cells
(Kanda and Tamaki, 1999). Estrogen may also directly affect B
lymphocyte subsets. In animal studies, estrogens increase bone
marrow progenitor B cells by protecting them from apoptosis
(Grimaldi et al., 2002; Medina et al., 2000), and by increasing the
survival of B cells (Grimaldi et al., 2002). In humans, estrogens
induce polyclonal activation of B cells. Speciﬁcally, estrogen
Fig. 4. The role of hormones in the sexual dimorphism in autoimmunity. The strong gender bias in autoimmune disease susceptibility could be due to the differential effects
of gender-speciﬁc hormones in contributing to disease, and the differential roles of these hormones relative to altered reproductive states. Estrogen, which is seen in high
levels during pregnancy, impacts immunity by modulating lymphocyte development and function, and promoting cytoprotection. These actions of estrogen could lead to
improved cell-mediated disease or worsened antibody-mediated disease. Progesterones and androgens exert anti-inﬂammatory and immunosuppressive effects respectively,
and this is generally beneﬁcial in autoimmune disease. Prolactin, which is high during pregnancy, induces pro-inﬂammatory effects, and this tends to worsen autoimmune
disease.
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cells. This occurs regardless of gender (Kanda and Tamaki, 1999;
Weetman et al., 1981). The role of estrogen in immunity has been
extensively reviewed (Bouman et al., 2005).
The potential cytoprotective role of estrogens may explain these
effects. Takao and colleagues showed that estrogen treatment
dose-dependently reversed the cytotoxic effects of TNFa in T cells.
In this study, the ER antagonist ICI-172.780 abolished the cytopro-
tective effects of 17b-estradiol on T cells (Takao et al., 2005).
Numerous reports demonstrate protective actions of estrogens on
the EAE mouse model of MS (Bebo et al., 2001; Ito et al., 2001;
Jansson et al., 1994). In this model of MS, inﬂammation is mediated
by T lymphocytes that react to CNS and brain-derived autoanti-
gens. To delineate the mechanisms through which estrogen may
be cytoprotective, Lélu and colleagues demonstrate that endoge-
nous estrogens limit the recruitment of blood-derived inﬂamma-
tory cells (CD4 + T cells) into the CNS (Lelu et al., 2010). Thus,
estrogen may protect the brain from damage following inﬂamma-
tory insults. This may underlie the potential cytoprotective effects
of estrogen during pregnancy.
In females, circulating levels of estrogens change dramatically
relative to reproductive function. This is important, as varying
levels of exposure to estrogens greatly affects immunity. At high
concentrations (such as in pregnancy), estrogen inhibits the Th-1
pro-inﬂammatory pathways (including TNFa, IL-1b and IL-6) and
stimulates Th-2 anti-inﬂammatory pathways (including IL-4, IL-
10 and TGFb). Conversely, at low levels (as seen after menopause),
estrogen stimulates pro-inﬂammatory pathways (including TNFa
and IL1-b) (Straub, 2007).
Relative to autoimmunity, estrogens may differentially impact
incidence across age and reproductive capacity. Second to this,
the actions of estrogens on inﬂammatory and immune responses
may change relative to the presence of autoimmune diseases. For
example, T lymphocytes from patients with SLE, but not from
healthy controls, are activated via ERa and ERb-speciﬁc agonists
(Rider et al., 2006). While evidence conﬁrms the role of estrogens
in immunity, suggesting that they may play an important role in
autoimmunity, the mechanisms through which estrogens may
directly or indirectly mediate autoimmune responses remain
unknown. Elucidation of this will require more substantiveevidence demonstrating a direct involvement of estrogen in the
incidence of autoimmune disease.
The high female to male incidence rate for SLE (Fig. 1), coupled
with a dramatic reduction in gender ratios prior to puberty or fol-
lowing menopause (both conditions are associated with a reduc-
tion in circulating estrogen levels) has contributed to anecdotal
evidence suggesting that estrogen mediate immunity speciﬁc to
autoimmune diseases. This has been substantiated by studies
assessing the effects of estrogens on tissue collected from patients
suffering from autoimmune diseases. For example, lymphocytes
collected from SLE patients are more sensitive to the actions of
physiological levels of E2, whereas E2 may differentially modify
signaling pathways coupled to disease onset and severity in T cells
from SLE patients (reviewed in (Pierdominici and Ortona, 2013)).
Moreover, documented associations between autoimmune dis-
eases and various facets of estrogen signaling provide reason for
further assessment of potential causes. For example, in MS, ER
expression in the thymus changes dramatically (Zoller and Kersh,
2006), whereas estrogen concentrations in synovial ﬂuid is mark-
edly increased in RA patients (Cutolo et al., 2004). However, this
does not necessarily mean that altered levels of endogenous estro-
gens will increase the risk for developing SLE. For example, the
incidence of SLE does not change relative to pregnancy and birth
rate (Cooper et al., 2002). Moreover, while the incidence of lupus
ﬂares in patients with existing SLE increase during pregnancy
(Walker, 2007), this is not necessarily associated with alterations
in circulating levels of estrogens. For example, Doria et al. (2006)
demonstrated that estrogen levels in SLE patients may not rise dur-
ing the second and third trimesters of pregnancy, and thus disease
ﬂares that occur at this time cannot be directly associated with
altered circulating levels of estrogens (Doria et al., 2006).
Accordingly, alterations in physiology not coupled to endogenous
estrogen may underlie autoimmune disease associations. To this
extent, the potential role of estrogen in the development of
autoimmune disease may be better identiﬁed when considering
exogenous estrogens, estrogen-like compounds, or modiﬁers of
estrogen action.
Immune responses may be compromised by naturally occurring
exogenous estrogens (phyto/myco-estrogens), or by synthetic
estrogen-like compounds (xenoestrogens) (reviewed in
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Vandenberg et al., 2012)). These compounds are widely found in
products used in the production of food and around the home,
including detergents, plastics, pesticides, and industrial chemicals.
While less potent than endogenous estrogens, these compounds
can accumulate in adipose tissue, where they may exert potent
effects on immunity (Chighizola and Meroni, 2012). Existing evi-
dence showing an involvement in phyto-, myco- or xenoestrogens
in autoimmune disease rely predominantly on epidemiological evi-
dence, or exposure studies conducted on animal models. Thus, it
remains unknown to what extent these compounds contribute to
autoimmune disease in the real world. Moreover, epidemiological
studies, and resulting assessment of the effects of exogenous estro-
gens on immune function may not necessarily accurately predict
direct estrogenic effects on autoimmune disease incidence.
Perhaps one of the most revealing cases of associations between
autoimmune disease and estrogen replacement therapy comes
from the use of Diethylstilbestrol (DES).
DES is a synthetic estrogen, historically used to reduce risk of
complications to pregnancy, to assist with postpartum lactation,
and for the treatment of other postmenopausal symptoms. Not
only did DES not improve pregnancy outcomes (Bamigboye and
Morris, 2003), it contributed to a number of complications. For
example, as a transplacental carcinogen, the exposure to DES con-
tributed to a signiﬁcant rise in the development of rare vaginal
tumors (Herbst et al., 1971). Animal studies showed that DES has
a profound effect on immune responses (Luster et al., 1978),
conﬁrming fears that DES exposure may have contribute to auto-
immune diseases in humans. However, while conﬁrming that
females exposed to DES developed a number of autoimmune disor-
ders, the incidence was relatively low (Noller et al., 1988). This was
veriﬁed in more recent observations (Strohsnitter et al., 2010),
where the relative rise in incidence in RA in DES exposed females
below 45 years of age was offset by a much lower incidence in
older females. Thus, while animal studies demonstrate a signiﬁcant
risk for autoimmunity following DES exposure, data from humans
provide little support for an association between the development
of an autoimmune disease and exposure to DES. This important
case highlights the need for rigorous assessment and careful
validation of autoimmune incidence following exogenous estrogen
exposure. This is of considerable importance, as estrogen-mediated
therapies may effectively alleviate complications with autoim-
mune diseases. In this instance, unsubstantiated concerns regard-
ing the use of estrogen-containing oral contraceptives may in
fact be to the detriment of women suffering from autoimmune
conditions, and in particular SLE.
While the potential beneﬁts of estrogen therapy in some auto-
immune diseases are recognized, it should be noted that conﬂicting
observations make the interpretation of the extent of potential
beneﬁts difﬁcult. Moreover, identiﬁcation of potential beneﬁcial
effects of estrogen on autoimmune disease requires careful consid-
eration of the type and severity of the condition. For example,
while estrogen therapy in MS (Sicotte et al., 2002) and RA
(Bijlsma et al., 1987) may be beneﬁcial, estrogen appears to
enhance disease severity in SLE. Thus, blockade of ER in SLE is
beneﬁcial (Abdou et al., 2008). Similarly, while the use of contra-
ceptives may protect against RA (Vandenbroucke et al., 1982),
some evidence suggest that the beneﬁcial effects are limited to
females under 35 years of age (Spector et al., 1990), or to females
that used contraceptives earlier in life (Hazes et al., 1990). In this
latter study, it was concluded that current use in older females
has no beneﬁts. Accordingly, estrogen-containing contraceptives
for the prevention of RA may only be of some beneﬁt to females
at childbearing age. Studies that directly assess this are however
scarce, and current observations are not promising. For example,
estrogen treatment (using lynestrenol plus ethinyl estradiol) ofwomen with RA for 6 months did not signiﬁcantly improve symp-
toms (Hazes et al., 1989).
As with the use of oral contraceptives, conﬂicting reports exist
regarding the value and risk of hormone replacement therapy
(HRT) in women to treat autoimmune diseases. For example, HRT
does not appear to impact the ongoing course of disease in MS
(Holmqvist et al., 2006), or the risk of developing RA (Walitt
et al., 2008). HRT is thought to beneﬁt postmenopausal women
with inﬂammatory bowel disease (Kane and Reddy, 2008), increase
bone mineral density in women with PBC (Ormarsdottir et al.,
2004), and improve incidence of isolated pulmonary hypertension
in post-menopausal women with systemic sclerosis (Beretta et al.,
2006). Conversely, in SLE, HRT may increase the risk of thrombosis
(Fernandez et al., 2007; Sanchez-Guerrero et al., 2007). Current
clinical trials assessing the potential roles of estrogens in prevent-
ing or minimizing disease impact for other autoimmune diseases
(for example ongoing efforts to assess the impact of estriol in
Relapsing Remitting Multiple Sclerosis, ClinicalTrials.gov Identi-
ﬁer: NCT00451204) will shed light on the value of estogen-medi-
ated effects on autoimmunity.
3.4.2. Progesterone
Progesterone belongs to the class of steroid hormones known as
progestogens, named for their function in gestation (pro-gesta-
tion). Progesterone is produced predominantly in the gonads and
adrenal gland, and in pregnancy in the placenta. While critically
involved in pregnancy, detectable levels of progesterone are in cir-
culation in females throughout the menstrual cycle and in males in
levels similar to that seen in females during the follicular phase of
the menstrual cycle. The actions of progesterone in reproduction
are varied. In addition to directly regulating reproductive function
(including oocyte maturation, endometrial differentiation, embry-
onic implantation, placental growth etc.), progesterone may also
alter the actions of other steroid hormones at this time (Steyn
et al., 2008). Accordingly, interaction of progesterone with target
tissues may occur via indirect mechanisms.
Progesterone acts via its cytosolic receptor, the progesterone
receptor (PR). This receptor belongs to the nuclear hormone recep-
tor superfamily of transcription factors. Ligand binding of PR
induces changes in gene expression through direct binding to pro-
moter elements or through protein–protein interactions with other
transcription factors. Of interest, recent observations highlight that
actions of progestins (including progesterone) may occur indepen-
dent of the PR, therefore arguing for non-genomic interactions (Li
et al., 2004). As summarized by Hughes (2012), the actions of pro-
gesterone on immunity are best described by the wide distribution
of PRs on immune cells, including granulocytes, NK cells, dendritic
cells, T-cells and B cells (Hughes, 2012), although non-genomic
interactions may occur.
In general, the effects of progesterone in immunity are anti-
inﬂammatory. Of these, known effects include the promotion of
apoptosis and inhibition of IFNc production from NK cells
(Arruvito et al., 2008), the inhibition of macrophage activity
(Pisetsky and Spencer, 2011), the modulation of myeloid dendritic
cell activity (reviewed in (Hughes and Clark, 2007)), the inhibition
of glucocorticoid-mediated thymocyte apoptosis (McMurray et al.,
2000), the reduction of nitric oxide production (Miller et al., 1996)
and the expression of toll-like receptors (TLR) by macrophages
(Jones et al., 2008), the differentiation of Th2 cells in vitro
(Piccinni et al., 1995), and the expression of the co-stimulatory
molecules CD80, CD86 and CD40, as well as MHC II (Ivanova
et al., 2005; Liang et al., 2006). The role of progesterone in immu-
nity was recently reviewed (Hughes, 2012).
As with estrogens the potential actions of progesterone on
autoimmunity are more commonly deﬁned in context of ﬂuctua-
tions in endogenous progesterone levels, dictated by changes in
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associated with remarkable changes in maternal immunity, and
may contribute to changes in immune responses. In general, the
effects of progesterone in immunity are anti-inﬂammatory. As with
estrogens, the potential effects of progesterone may also vary rel-
ative to disease severity and type. For example, progesterone pro-
tects against disease onset in gonadectomised lupus-prone NZB/W
mice (a model wherein mice spontaneously develop an autoim-
mune disorder similar to SLE) (Roubinian et al., 1978), whereas
in CIA rats (a common rat model for arthritis), progesterone alone
had no effect while reducing the beneﬁcial effects of estrogen
(Ganesan et al., 2008). Similarly, continuous progesterone adminis-
tration to pre-autoimmune NZB/W mice delayed the development
of pathogenic serum anti-DNA antibodies and spontaneous auto-
immune disease and death (Hughes and Clark, 2007). In humans,
combined estrogen and progesterone hormone replacement
therapy may cause lupus ﬂares in post-menopausal women
(Buyon et al., 2005), whereas a current clinical trial is assessing
the potential beneﬁts of progestin treatment to prevent post-
partum ﬂares in women with MS (Vukusic et al., 2009) (Results
from this trial are pending (ClinicalTrials.gov Identiﬁer:
NCT00127075)). Given this variable response, substantive research
is needed before we can deﬁne the contribution of or treatment of
autoimmune diseases using therapies targeting progesterone.
3.4.3. Androgens
Androgens are steroid hormones commonly associated with the
development of masculine characteristics; implicated in testes for-
mation, spermatogenesis, and the deposition of lean muscle mass
at the expense of adipose. In males and females, androgens main-
tain bone mass while impacting behavior (including aggression).
Importantly, androgens are the precursors of all estrogens. While
generally present in high levels in males, androgens decline with
increasing age (Mitchell et al., 1995), whereas low circulating lev-
els of androgens persist throughout life in females (Davison et al.,
2005). As with estrogen and progesterone, androgens may act via
genomic (acting through the androgen receptor) and non-genomic
mechanisms (Lutz et al., 2003).
The actions of androgens on immune function may vary
depending on the type of androgen used, the dosage administered,
and the timing of administration. For example, some studies report
immunosuppressive effects (Fujii et al., 1975; Olsen and Kovacs,
1996; Paavonen, 1994), whereas endogenous androgens are also
thought to be immunostimulatory (Calabrese et al., 1989). Testos-
terone reduces the proliferation and differentiation of lymphocytes
(Sakiani et al., 2013; Sthoeger et al., 1988; Wyle and Kent, 1977),
and the use of androgens may suppress immunoglobulins, and in
particular IgA (Calabrese et al., 1989; Hirota et al., 1976). Andro-
gens, including supraphysiological doses of testosterone may inhi-
bit the cytotoxic activity of NK cells (Callewaert et al., 1991;
Marshall-Gradisnik et al., 2008; Sulke et al., 1985). Given that the
effects of androgens may vary considerably relative to the level
of exposure, and that multiple factors may contribute to the
immune proﬁle in females, the potential role of endogenous andro-
gens in gender speciﬁc immune function remains unknown.
Androgen levels are higher in males, and autoimmune incidence
is generally lower. Thus, it is thought that androgens may to some
extent protect against autoimmunity. Indeed, gonadectomy of
male NZB/W mice result in overt autoimmunity and earlier death,
whereas treatment with androgens in ovariectomised female NZB/
W mice reduced mortality (Roubinian et al., 1977). In humans,
transdermal treatment with testosterone for 1 year was of some
beneﬁt to men with MS, slowing cognitive decline and brain atro-
phy. Treatment, however, did not affect the number or volume of
enhancing lesions (Sicotte et al., 2007). In females with SLE,
testosterone administration via skin patches for 12 weeks did notsigniﬁcantly improve disease severity (Gordon et al., 2008),
whereas the impact of dehydroepiandrosterone (DHEA) treatment
in SLE was inconsistent. For example, while initial reports showed
that oral DHEA treatment (200 mg/day for 6 months) improved SLE
Disease Activity Index (SLEDAI) scores and overall assessment
scores in patients (van Vollenhoven et al., 1994), subsequent dou-
ble-blinded studies from the same group were unable to corrobo-
rate these results (van Vollenhoven et al., 1995, 1999). Of
interest, a larger multicenter randomized, double-blind placebo
controlled trial showed signiﬁcant improvements in assessment
scores from DHEA treated female patients (200 mg/day for
6 months), corresponding with a signiﬁcant reduction in disease
ﬂares (Chang et al., 2002). Importantly, DHEA is a precursor of both
androgens and estrogens, and thus these modest effects may not
necessarily involve direct androgenic roles. In light of potential
negative effects on HDL cholesterol (Casson et al., 1998), coupled
with the increased risk of developing atherosclerotic heart disease
in SLE patients (van Leuven et al., 2006), it is critical that the long-
term ramiﬁcation on cardiovascular health be considered before
recommending DHEA as a treatment option for SLE.
3.4.4. Prolactin
While predominantly secreted from the anterior pituitary gland,
immune cells including lymphocytes secrete prolactin (Chavez-
Rueda et al., 2005; Vera-Lastra et al., 2002). The prolactin receptor,
a member of the cytokine receptor superfamily, is found on mono-
cytes and T lymphocytes, and other cells of the immune system
(Jara et al., 1991). Thus, while prolactin predominantly acts on the
brain and within the mammary gland to ensure physiological adap-
tation essential for sustained maternal behavior and lactation
(Grattan et al., 2008), it may play an important role in immunity,
and thus pregnancy associated changes in autoimmunity.
Functionally, the paracrine actions of prolactin produced within
lymphocytes may mediate important immunological effects. For
example, prolactin is able to induce the proliferation of lympho-
cytes, whereas inactivation of prolactin action through adminstra-
tion of neutralizing antibodies signiﬁcantly decreases the
activation and proliferation of T lymphocytes (Chavez-Rueda
et al., 2005). Within the T lymphocytes, prolactin mediates T-bet,
an essential transcription factor involved in the production of
Th1-type cytokines, including IFN (Tomio et al., 2008). Thus, prolac-
tin may stimulate T-cell mediated inﬂammatory reactions (Tomio
et al., 2008). However, at high concentrations, prolactin may inhibit
the proinﬂammatory activation of T helper cells (Tomio et al., 2008).
Prolactin may enhance autoimmune disease, whereas serum
levels of prolactin may increase as a consequences of autoimmune
disease (Orbach and Shoenfeld, 2007). For example, hyperprolacti-
nemia is seen in autoimmune rheumatic diseases (ARD) including
SLE, RA, systemic sclerosis, SS, T1D, GD, HT, celiac disease, and MS
(Orbach et al., 2012). Elevated levels of prolactin was found in the
CSF in SLE patients with neuropsychiatric lupus (Jara et al., 1998),
while hyperprolactinemia is associated with activity of SLE in preg-
nancy (Jara et al., 2001). Of interest, hyperprolactinemia in patients
with pituitary tumors or following therapy with antipsychotic
drugs is associated with raised levels of thyroid autoantibodies
(Poyraz et al., 2008). Associations between prolactin and autoim-
munity are somewhat corroborated by animal studies, wherein
prolactin treatment often worsens disease severity. For example,
disease severity in NZB/Wmice increases following prolactin treat-
ment, and improves following treatment with bromocriptine (an
ergoline derivative used to suppress endogenous prolactin produc-
tion) (McMurray et al., 1991).
Attempts to treat human autoimmune disease with bromocrip-
tine have produced some positive results. Notably, in some SLE
patients bromocriptine treatment reduces disease ﬂares (Alvarez-
Nemegyei et al., 1998; McMurray et al., 1995). More recently, it
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patients reduce disease ﬂares (Yang et al., 2003), whereas this pilot
clinical data suggest that bromocriptine treatment may prevent
complications in pregnancy including preterm birth and active dis-
ease (Jara et al., 2007). Given the potential value of bromocriptine
and other prolactin antagonists in the treatment of autoimmunity,
further studies to delineate the mechanisms by which PRL affects
autoimmune disease activity are of critical importance.3.5. The environment
Environmental exposure can interact with the genotype of
(Selmi et al., 2012), and can inﬂuence the prevalence and inﬂuence
the risk of developing an autoimmune disease or the severity of
disease. Environmental candidates that have been proposed to play
a role in autoimmune diseases include infectious agents and chem-
icals (Chandran and Raychaudhuri, 2010; Costenbader et al., 2012;
Hemminki et al., 2010). Infectious agents are important in the
mosaic of autoimmunity (Shoenfeld et al., 2008), and a number
of autoimmune diseases have been linked to infection; rheumatic
fever presents after Streptococcus pyogenes infection (Fae et al.,
2006), primary anti-phospholipid syndrome patients have high
levels of IgM antibodies to rubella and Toxoplasma (Zinger et al.,
2009), diabetes is associated with Enterovirus (Richardson et al.,
2009), and active infections with Helicobacter pylori have been
observed in autoimmune gastritis (Annibale et al., 2001). Chemi-
cal/drug exposure, and immunotoxicity of such compounds are
linked to autoimmune disease. Chemicals that are commonly
found in cosmetics are associated with PBC (Rieger et al., 2006),
and acetaminophen may underlie the development of PBC by pro-
moting antimitochondrial autoantibodies (Leung et al., 2013).
Exposure to pesticides has been suggested to underlie the develop-
ment of autoantibodies (McConnachie and Zahalsky, 1991, 1992;
Thrasher et al., 1993), and lifetime exposure to insecticides is asso-
ciated with the presence of anti-nuclear antibodies (Rosenberg
et al., 1999). More recently, it has been found that exposure to
organic solvents is associated with an increased risk of developing
an autoimmune trait (Barragan-Martinez et al., 2012). Since these
exposures underlie the development of autoimmunity, gender dif-
ferences could occur if males and females have different types of
exposure or different biological response to these agents (Fig. 5).
We now discuss several examples.Fig. 5. The role of the environment in the sexual dimorphism in autoimmunity.
Men and women are exposed to environmental factors to varying degrees (e.g. men
tend to get more sunlight than women), and they have different physiological
responses to such factors. This differential exposure and response might inﬂuence
the prevalence and the risk of developing an autoimmune disease, or the severity of
disease between men and women.Vitamin D is an environmental factor that may underlie the
development of autoimmunity. Vitamin D has immunomodulatory
effects on T lymphocytes, B lymphocytes, and dendritic cells
(Arnson et al., 2007; Deluca and Cantorna, 2001). By signaling
through the vitamin D receptor, vitamin D reduces the effector T
cell response (Adorini, 2005; Gascon-Barre et al., 2003; Godfrey
et al., 2000; Lemire, 1992). Vitamin D also interacts with human
leukocyte antigen molecules, which predispose to MS
(Ramagopalan et al., 2009a). Evidence to support the a role for
sun exposure in autoimmunity is seen in SS (Erten et al., 2014),
RA (Gatenby et al., 2013), SLE (Kamen et al., 2006), and anti-
phospholipid syndrome (Andreoli et al., 2012; Piantoni et al.,
2012) where vitamin D deﬁciency is associated with disease or
increased risk of developing disease. Indeed, greater vitamin D3
synthetic rate resulting from higher intensity ultraviolet light at
high altitudes, may account for lower MS rates at higher altitudes
(Hayes et al., 1997). It must be noted however, that within any geo-
graphical location, exposure to sunlight between men and women
could vary, and this may be dependent on lifestyle factors, or occu-
pational choices. Given that men tend to have more unprotected
sun exposure (Hall et al., 1997), gender-speciﬁc responses to sun-
light may play a role in autoimmune disease. Another example of
differences in exposure to environmental triggers is the role of cos-
metics in PBC, where the exposure to cosmetics is much greater in
women than men. Other environmental agents that are implicated
in autoimmunity and that may have differential exposures in
males and females are mercury, pesticides and solvents (Pollard,
2012).4. Genetic aspects of the sexual dimorphism in autoimmunity
Genetic factors may contribute to the sexual dimorphism that is
seen in autoimmune disease. Such factors that might inﬂuence the
development of autoimmune disease may be related to susceptibil-
ity genes, chromosomal differences, or epigenetics. The presenta-
tion of multiple autoimmune diseases in a given individual or
family suggests that common genetic factors may prejudice an
individual to developing autoimmunity. The clustering of suscepti-
bility genes in conditions like MS and CD suggests that in some
cases, autoimmune diseases may be controlled by a set of suscep-
tibility genes (Becker et al., 1998).4.1. Interaction of genes and gender
The HLA genes are located in a region that includes a large
number of genes that are involved in the immune response. Asso-
ciations exist between HLA genes and a number of autoimmune
diseases including GD (Li and Chen, 2013), MG (Avidan et al.,
2013), MS (Cree, 2014), RA (Jin et al., 2014), and SLE (Deng et al.,
2013) amongst many others (Horton et al., 2004). The majority of
these associations are with HLA-DR and HLA-DQ genes (Gough
and Simmonds, 2007), which encode for proteins that play a cen-
tral role in presenting antigens to CD4 + T cells (Schendel and
Johnson, 1985). The association between HLA genes and autoim-
mune disease generally shows a gender bias toward females. In
MG, single nucleotide polymorphisms in the HLA-locus support
the premise that there is a female gender bias for increased risk
for MG (Avidan et al., 2013). Similarly, being female may further
the risk associated with HLA DR4 alleles in type 1 autoimmune
hepatitis, since females have a higher frequency of HLA DR4 than
men (Czaja and Donaldson, 2002). In MS, there is a strong associa-
tion between HLA-DR2, DQ6 in females (Celius et al., 2000), and in
chronic inﬂammatory demyelinating polyneuropathy the associa-
tion with HLA-DR2 is greater for females (Czaja and Donaldson,
2002). In RA, there is an association between disease and females
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however, there is a reversal in gender bias, with a higher HLA asso-
ciated genetic risk in men (Hughes et al., 2012).
Non-HLA genes are also associated with susceptibility to auto-
immune disease. Polymorphisms in cytotoxic T-lymphocyte anti-
gen-4 (CTLA-4), acid phosphatase locus 1 (ACP1), Discs large
homolog 5 (DLG5), interleukin-10 (IL-10), and apolipoprotein E
(APOE) are commonly observed. Genetic A/G polymorphisms in
CTLA-4 have been identiﬁed in AS (Huang et al., 2014), GD (Du
et al., 2013), and T/C polymorphisms may be associated with SLE
risk (Zhu et al., 2013). By contrast, there is no evidence to suggest
that CTLA-4 polymorphisms confer susceptibility to MS (Gyu Song
and Ho Lee, 2013). While the majority of studies that investigate
CTLA-4 polymorphisms in autoimmune disease do not necessarily
consider results relative to gender, CTLA-4 A/G polymorphisms
can modify maternal inheritance of the HLA-DR3 (Fajardy et al.,
2002).
Polymorphisms in ACP1 and DLG5 are associated with CD
(Browning et al., 2008; Stoll et al., 2004), and there is evidence of
a reduced susceptibility to CD in females who possess ACP1*A
alleles (Gloria-Bottini et al., 2007), and modest evidence of reduced
risk of CD in females with the DLG5 R30Q variant (Browning et al.,
2008). Polymorphisms in IL-10 are linked to severity of HT (Inoue
et al., 2013), RA (Hee et al., 2007), and primary SS (Qin et al.,
2013). While these studies do not stratify risk according to gender,
an AA -1087 IL-10 genotype appears to be more common in women
with RA (Padyukov et al., 2004). Polymorphisms in APOE are asso-
ciated with primary SS (Pertovaara et al., 2004) and MS (Cocco
et al., 2005; Raﬁei et al., 2012). Again, while not considered relative
to gender, female carriers of the apolipoprotein E epsilon4 allele
had a tendency for earlier onset of primary SS when compared to
female non-carriers (Pertovaara et al., 2004). In the case of MS
however, presence of the APOE alleles seems to favor females;
women carriers of the epsilon2 allele had reduced severity of dis-
ease (Kantarci et al., 2004), and cognitive decline is more promi-
nent in males who carry the epsilon4 allele (Savettieri et al., 2004).
The observations from these studies provide strong evidence to
support the notion that genetic risks underlie susceptibility to
some autoimmune diseases. While a large number of studies focus
on the involvement of HLA genes, it is becoming strikingly clear
that polymorphisms in non-HLA genes should also be taken into
account when considering the relationship between genetic factors
that predispose to autoimmune disease. Given the strong associa-
tions between HLA genes and non-HLA genes and autoimmune dis-
ease, future studies that investigate the genetic underpinning of
such diseases should be considered relative to gender.
4.2. The X chromosome in autoimmune disease
The X chromosome contains a large number of genes that are
involved in immunity (reviewed in (Fish, 2008; Libert et al.,
2010)). While females carry two X chromosomes, one X chromo-
some is inactivated early in embryogenesis. This allows for equal
gene expression dosage between males and females, but also
results in cellular mosaicism (Migeon, 2006). Consequently,
females may avoid any effects that arise from harmful gene-muta-
tions, and cellular mosaicism (arising from natural variations in
one gene that might result in two different alleles) may result in
added advantages in response to immune challenges (Migeon,
2006; Spolarics, 2007).
Autoimmune phenomena are observed in X-linked primary
immunodeﬁciencies. Thus it is likely that genes on the X chromo-
some may also play a role in autoimmunity (Bussone and
Mouthon, 2009; Carneiro-Sampaio and Coutinho, 2007; Mackay
and Rose, 2001). It has been suggested that X chromosome inacti-
vation, loss of X chromosomes or X monosomy may underlie thedevelopment of autoimmune disease. Skewed X chromosome inac-
tivation is observed in HT, GD (Brix et al., 2005; Chabchoub et al.,
2009; Ozcelik et al., 2006), sclerodoma (Ozbalkan et al., 2005; Uz
et al., 2008), RA (Chabchoub et al., 2009), and SS (Ozcelik, 2008),
but not in SLE (Huang et al., 1997) and MS (Knudsen, 2009;
Knudsen et al., 2007). Data from a number of studies suggest that
X chromosome monosomy rates may also underlie the female pre-
dominance in autoimmune diseases. In disease such as PBC, HT,
and GD, enhanced X monosomy rates have been observed in
peripheral blood cells (Invernizzi et al., 2004, 2005), but this is
not the case for SLE (Invernizzi et al., 2007). Skewed X chromosome
inactivation and monosomy appear to be more common in autoim-
mune thyroid diseases (Brix et al., 2005; Chabchoub et al., 2009;
Invernizzi et al., 2005; Ozcelik et al., 2006).
Males with two X chromosomes (Chagnon et al., 2006), or males
with two X chromosomes and a Y chromosome have also been
known to present with SLE (Lahita, 1999). Interestingly, SLE males
that are XXY, are similar to female SLE patients in that they have
increased oxidation of testosterone (Lahita, 1999). These observa-
tions support a role for the X chromosome in SLE.
4.3. The Y chromosome in autoimmune disease
Compared to the X chromosome, the Y chromosome has
received little attention in human autoimmunity. The Y chromo-
some accounts for a small portion of the human genome, and is
associated with male fertility and testis formation (Quintana-
Murci et al., 2001). While the Y chromosome is linked to the inher-
itance of human coronary heart disease (Charchar et al., 2012), the
majority of studies that have assessed the contribution of the Y
chromosome to autoimmunity has been conducted in mouse mod-
els of SLE (Lin et al., 2010; Murphy and Roths, 1979; Santiago-
Raber et al., 2008; Subramanian et al., 2006) and MS (Palaszynski
et al., 2005; Spach et al., 2009; Teuscher et al., 2006) (reviewed
in (McCombe et al., 2009)). Recent studies have found an age-
dependent loss of the Y chromosome in PBC (Lleo et al., 2013),
and in HT and GD (Persani et al., 2012). These observations further
support the role of the X chromosome in autoimmune disease.5. Parental inheritance/transmission in autoimmunity
Maternal and paternal inheritance occurs in autoimmune dis-
ease. While one study in Canada has found that there is equal
inheritance of MS from affected fathers and mothers (Herrera
et al., 2007), and paternal inheritance in MS has been reported
(Marrosu et al., 2004), the majority of studies assessing parent-
of-origin effects in MS are more indicative of a strong maternal
effect for risk of inheritance (Ebers et al., 2004), and predominant
maternal inheritance (Chao et al., 2010; Ebers et al., 2004;
Herrera et al., 2008; Hoppenbrouwers et al., 2008). Inheritance of
autoimmune disease in T1D however, takes on a paternal domi-
nance (MacDonald et al., 1986). Islet autoimmune antibodies are
more frequently transmitted via diabetic fathers (Yu et al., 1995),
paternal inheritance of the insulin gene B allele confers protection
from T1D (Pugliese et al., 1994), while paternal inheritance of the
11p15.5 region of the insulin gene (IDDM2) confers susceptibility
to T1D (Bui et al., 1996).
5.1. Causative factors for parental inheritance of autoimmunity
The interaction of genetic and environmental factors may
underlie parental inheritance of autoimmunity. In the case of
maternal inheritance, mitochondrial DNA could play a role. While
studies addressing mitochondrial DNA variants with autoimmune
disease are limited, MS has been associated with the mitochondrial
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2008). Interestingly, variants in mitochondrial ND2 and ATP6
genes have also been found to be associated with MS and SLE, sug-
gesting that these two diseases may share a common mitochon-
drial genetic background.
In addition to genetic factors, environmental factors may also
contribute to parental inheritance of autoimmunity
(Hoppenbrouwers et al., 2008). Some of the best examples of envi-
ronmental inﬂuence in parental transmission in autoimmunity
have come from studies in MS cohorts. The development of MS
in affected offspring may arise from in utero exposure to epigenetic
changes that might result from environmental inﬂuences on the
mother (e.g. timing of birth is associated with risk of MS) (Willer
et al., 2005). This is discussed further below.6. Epigenetics in autoimmunity
Epigenetics relates to the stable and heritable patterns of gene
expression that are not due to changes in the original DNA
sequence. Altered gene expression may be persistent, but not
permanent, and the epigenome of the cell can be deﬁned by meth-
ylation, histone modiﬁcation and micro RNA (miRNA) proﬁle
(Goldberg et al., 2007; Jiang et al., 2004; Lu, 2013). Epigenetic
changes that arise in autoimmune disease can be related to the
sex of the parent, or can result from external factors. With respect
to parental gender, epigenetic changes occur via genetic imprinting,
whereby genes inherited either from the father or mother are
imprinted and inactivated, or when transcripts from either the
maternal or paternal chromosome are expressed in a monoallelic
fashion (Camprubi andMonk, 2011). Extrinsic inﬂuences in autoim-
mune disease include tobacco smoke, exposure to sunlight, and diet
(Ellis et al., 2014). Below, we discuss evidence that indicates a role
for genomic imprinting and epigenetics in driving sexual dimor-
phism in autoimmune disease.
6.1. Genomic imprinting as a cause for autoimmunity
Genomic imprinting is the allele-speciﬁc expression of genes in
a parent-of-origin fashion. It has been suggested that the genetics
underlying HLA susceptibility in T1D may exhibit parental inheri-
tance; Pani and colleagues suggest that the maternal HLA-DQ2 or
DQ8 alleles are risk factors for T1D (Pani et al., 2002). For psoriatic
arthritis, genetic linkage analysis suggests that there is imprinted
transmission at chromosome 16q that is of paternal origin
(Karason et al., 2003).
Imprinting of miRNAs may also underlie autoimmunity. Micro
RNAs play important roles in the post-transcriptional regulation
of gene expression. In this regard, a loss of miRNAs or the deregu-
lation of miRNAs could contribute to altered autoimmune gene
expression that would result in the development of autoimmune
disease. Indeed, imprinted miRNAs that may regulate autoimmune
disease associated genes have been identiﬁed for MS, RA, SLE, and
T1D (Camprubi and Monk, 2011). Given that there is differential
hormonal and chromosomal regulation of miRNAs between males
and females (Sharma and Eghbali, 2014), it is highly likely that
miRNA imprinting could contribute to the sexual dimorphism seen
in autoimmune disease.
6.2. Extrinsically driven epigenetic gene modiﬁcations in
autoimmunity
External stimuli including tobacco smoke, sunlight, and diet
that lead to DNA modiﬁcation could explain gender differences in
autoimmune disease. Smoking is associated with an increased risk
for RA in both men and women when compared to non-smokers(Sugiyama et al., 2010), and increased risk of MS (in women stud-
ied) (Hernan et al., 2001). Moreover, smoking has been found to be
a risk factor for relapsing–remitting MS (Hernan et al., 2005). Expo-
sure to lower levels of sunlight (Hammond et al., 1988; Kurtzke
et al., 1979; Taylor et al., 2010; van der Mei et al., 2003; Vukusic
et al., 2007), season of birth (Dobson et al., 2013; Willer et al.,
2005), low maternal exposure to sunlight (Staples et al., 2010),
and low levels of vitamin D (van der Mei et al., 2007) have been
well established to be associated with increased risk for MS. Recent
studies assessing dietary intake of vitamin D in women with MS
report that higher levels of vitamin D are associated with reduced
risk (Munger et al., 2004), and assessment of micronutrient intake
has provided insight into the geographical blueprint of autoim-
mune disease in China (Qin et al., 2009). While it is easy to specu-
late that varying exposure to extrinsic triggers would occur
between males and females, earlier adoption of smoking in men
(Zang and Wynder, 1996), increased unprotected exposure to sun-
light in men (Hall et al., 1997), and different dietary habits
between men and women (Dynesen et al., 2003; Ferraro and
Vieira, 2010; Friel et al., 2005) would support the notion that dif-
ferential exposure to extrinsic factors may play a role in gender
bias in autoimmune disease.7. Conclusion
The gender differences that exist in autoimmunity tend to fol-
low a female bias. A number of factors may underlie this striking
gender difference. The clear differences between the female and
male immune systems would suggest that the increased immune
reactivity in females might predispose them to developing autoim-
mune disease. This may be explained in part by the effects of sex
hormones since estrogen suppresses Th1-dependent disease, but
potentiates Th2-dependent diseases. Accordingly, differences in
reproductive function, and pregnancy in women, may also explain
gender differences in autoimmunity. While the impact of micro-
chimerism during pregnancy in autoimmune disease remains to
be understood, parental inheritance, mitochondrial inheritance,
genomic imprinting and chromosomal inactivation could also play
a role. Finally, extrinsic epigenetic inﬂuences and more speciﬁcally,
the level of exposure to external factors and the subsequent
response to such factors might inﬂuence susceptibility to autoim-
mune disease. In conclusion, the striking evidence of gender differ-
ences in autoimmune disease should dictate that future studies
considering incidence, prevalence, severity, mortality, disease
mechanisms and potential therapies in autoimmunity be stratiﬁed
according to gender.Acknowledgment
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